Standard BioTools

Standard BioTools Goodwill/Assets

The Goodwill to Total Assets Ratio of Standard BioTools (LAB) as of Oct 8, 2026 is 18.18 %. In the previous year, Goodwill to Total Assets Ratio was 32.91 % — a change of -44.77% (lower).

Goodwill/Assets

18.18 %

YoY

-44.77%

Last updated:

Goodwill to Total Assets Ratio of Standard BioTools is 2024 18.18 % . Goodwill to Total Assets Ratio of Standard BioTools was 2023 32.91 % . It decreases by -44.77% lower compared to the previous year.

The Standard BioTools Goodwill/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill/Assets
Date
Goodwill/Assets
Jan 1, 2017
36.23 USD
Jan 1, 2018
34.29 USD
Jan 1, 2019
39.31 USD
Jan 1, 2020
32.81 USD
Jan 1, 2021
38.65 USD
Jan 1, 2022
27.22 USD
Jan 1, 2023
32.91 USD
Jan 1, 2024
18.18 USD
The Standard BioTools Goodwill/Assets history
YEARGoodwill/AssetsYoY
18.18 %-44.77%
32.91 %+20.89%
27.22 %-29.57%
38.65 %+17.80%
32.81 %-16.54%
39.31 %+14.67%
34.29 %-5.37%
36.23 %+6.63%
33.98 %+21.11%
28.06 %+9.84%
25.54 %—
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Goodwill to Total Assets Ratio of Standard BioTools is 18.18 % in 2024.

Goodwill to Total Assets Ratio of Standard BioTools changed from 32.91 % to 18.18 %, representing a -44.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools